Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-7624 in Healthy Adult Participants
← catalyst calendarNCT06920693 · readout in 11 d
Sponsored by Generate Biomedicines (industry) · GENB — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
40estimated
Sites
1
Country
Australia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-27 | actual | When the study began enrolling |
| Primary completion | 2026-08-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-04-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Atopic Dermatitis (AD)
Interventions
- Drug: GB-7624
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFComposite Outcome: To assess the safety and tolerability of single doses of GB-7624 administered subcutaneously (SC) in healthy volunteers.
measured Day -1 to Day 360
Composite Outcome: To assess the safety and tolerability of multiple doses of GB-7624 administered SC in healthy volunteers
measured Day -1 to Day 360
Permalink · GENB's whole pipeline · Catalyst calendar · Every registered study · What changed